Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients

Advanced Drug Delivery Reviews

Volumn 85, Issue , 2015, Pages 7-23

  Ciofu, Oana ^a   Tolker Nielsen, Tim ^a   Jensen, Peter Østrup ^a   Wang, Hengzhuang ^a,b   Høiby, Niels ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

Biofilm; Cystic fibrosis; Pseudomonas aeruginosa

Indexed keywords

ANTIBIOTICS; BACTERIA; BIOLOGICAL ORGANS; DRUG DELIVERY;

ANTIMICROBIAL RESISTANCES; CHRONIC INFLAMMATION; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; PHARMACOKINETICS AND PHARMACODYNAMICS; PSEUDOMONAS AERUGINOSA; QUORUM-SENSING INHIBITORS; RESPIRATORY TRACT INFECTIONS;

BIOFILMS;

AMIKACIN; ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CHLORZOXAZONE; CIPROFLOXACIN; COLISTIN; FOSFOMYCIN; FURANONE DERIVATIVE; HYDROXYL RADICAL; IMIPENEM; LEVOFLOXACIN; MEROPENEM; NIFUROXAZIDE; NORFLOXACIN; PIPERACILLIN; SALICYLIC ACID; TETRACYCLINE; TOBRAMYCIN; TRIMETHOPRIM; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BIOFILM; BURKHOLDERIA; CELL DENSITY; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; ESCHERICHIA COLI; GENE EXPRESSION; HUMAN; IMMUNE SYSTEM; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUORUM SENSING; RESPIRATORY TRACT INFECTION; REVIEW; CONFOCAL MICROSCOPY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; LUNG; MICROBIOLOGY; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS;

ANTI-BACTERIAL AGENTS; BIOFILMS; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; LUNG; MICROSCOPY, CONFOCAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUORUM SENSING; RESPIRATORY TRACT INFECTIONS;

EID: 84930089623     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.11.017     Document Type: Review

References (249)

1. Bell S.C., De B.K., Amaral M.D. New pharmacological approaches for cystic fibrosis: Promises, progress, pitfalls. Pharmacol. Ther. 2014, (Epub ahead of print paper).
2. Hoegger M.J., Fischer A.J., McMenimen J.D., Ostedgaard L.S., Tucker A.J., Awadalla M.A., Moninger T.O., Michalski A.S., Hoffman E.A., Zabner J., Stoltz D.A., Welsh M.J. Cystic fibrosis. Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis. Science 2014, 345:818-822.
3. Boucher R.C. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur. Respir. J. 2004, 23:146-158.
4. Høiby N., Krogh Johansen H., Moser C., Song Z., Ciofu O., Kharazmi A. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect. 2001, 3:23-35.
5. Armstrong D.S., Hook S.M., Jamsen K.M., Nixon G.M., Carzino R., Carlin J.B., Robertson C.F., Grimwood K. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr. Pulmonol. 2005, 40:500-510.
6. Armstrong D.S., Grimwood K., Carzino R., Carlin J.B., Olinsky A., Phelan P.D. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 1995, 310:1571-1572.
7. Høiby N., Pressler T. Emerging pathogens in cystic fibrosis. European respiratory monograph in cystic fibrosis 2006, 66-78. A.K. Webb, F. Ratjen (Eds.).
8. Hansen C.R., Pressler T., Hoiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15years experience. J. Cyst. Fibros. 2008, 7:523-530.
9. Hoffmann N., Rasmussen T.B., Jensen P.O., Stub C., Hentzer M., Molin S., Ciofu O., Givskov M., Johansen H.K., Hoiby N. Novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis. Infect. Immun. 2005, 73:2504-2514.
10. Jelsbak L., Johansen H.K., Frost A.L., Thogersen R., Thomsen L.E., Ciofu O., Yang L., Haagensen J.A., Hoiby N., Molin S. Molecular epidemiology and dynamics of Pseudomonas aeruginosa populations in lungs of cystic fibrosis patients. Infect. Immun. 2007, 75:2214-2224.
11. Bjarnsholt T., Jensen P.O., Fiandaca M.J., Pedersen J., Hansen C.R., Andersen C.B., Pressler T., Givskov M., Hoiby N. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr. Pulmonol. 2009, 44:547-558.
12. Høiby N., Ciofu O., Bjarnsholt T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol 2010, 5:1663-1674.
13. Hansen C.R., Pressler T., Nielsen K.G., Jensen P.O., Bjarnsholt T., Hoiby N. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J. Cyst. Fibros. 2010, 9:51-58.
14. Schwab U., Abdullah L.H., Perlmutt O.S., Albert D., Davis C.W., Arnold R.R., Yankaskas J.R., Gilligan P., Neubauer H., Randell S.H., Boucher R.C. Localization of Burkholderia cepacia Complex Bacteria in Cystic Fibrosis Lungs and Interactions with Pseudomonas aeruginosa in Hypoxic Mucus. Infect. Immun. 2014, 82:4729-4745.
15. Foster J.S., Kolenbrander P.E. Development of a multispecies oral bacterial community in a saliva-conditioned flow cell. Appl. Environ. Microbiol. 2004, 70:4340-4348.
16. Anderson G.G., Palermo J.J., Schilling J.D., Roth R., Heuser J., Hultgren S.J. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 2003, 301:105-107.
17. Høiby N., Döring G., Schiøtz P.O. The role of immune complexes in the pathogenesis of bacterial infections. Annu. Rev. Microbiol. 1986, 40:29-53.
18. Hall-Stoodley L., Hu F.Z., Gieseke A., Nistico L., Nguyen D., Hayes J., Forbes M., Greenberg D.P., Dice B., Burrows A., Wackym P.A., Stoodley P., Post J.C., Ehrlich G.D., Kerschner J.E. Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. JAMA 2006, 296:202-211.
19. Sanderson A.R., Leid J.G., Hunsaker D. Bacterial biofilms on the sinus mucosa of human subjects with chronic rhinosinusitis. Laryngoscope 2006, 116:1121-1126.
20. Gristina A.G., Oga M., Webb L.X., Hobgood C.D. Adherent bacterial colonization in the pathogenesis of osteomyelitis. Science 1985, 228:990-993.
21. Nickel J.C., Olson M.E., Barabas A., Benediktsson H., Dasgupta M.K., Costerton J.W. Pathogenesis of chronic bacterial prostatitis in an animal model. Br. J. Urol. 1990, 66:47-54.
22. Kirketerp-Moller K., Jensen P.O., Fazli M., Madsen K.G., Pedersen J., Moser C., Tolker-Nielsen T., Hoiby N., Givskov M., Bjarnsholt T. Distribution, organization, and ecology of bacteria in chronic wounds. J. Clin. Microbiol. 2008, 46:2717-2722.
23. Darouiche R.O. Device-associated infections: a macroproblem that starts with microadherence. Clin. Infect. Dis. 2001, 33:1567-1572.
24. Pamp S.J., Gjermansen M., Tolker-Nielsen T. The biofilm matrix:a sticky framework. The biofilm mode of life:mechanisms and adaptation, Norfolk, UK 2007, S. Kjelleberg, M. Givskov (Eds.).
25. Anwar H., Costerton J.W. Enhanced activity of combination of tobramycin and piperacillin for eradication of sessile biofilm cells of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1990, 34:1666-1671.
26. Cochrane D.M., Brown M.R., Anwar H., Weller P.H., Lam K., Costerton J.W. Antibody response to Pseudomonas aeruginosa surface protein antigens in a rat model of chronic lung infection. J. Med. Microbiol. 1988, 27:255-261.
27. Hoyle B.D., Costerton J.W. Bacterial resistance to antibiotics: the role of biofilms. Prog. Drug Res. 1991, 37:91-105.
28. Ceri H., Olson M.E., Stremick C., Read R.R., Morck D., Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J. Clin. Microbiol. 1999, 37:1771-1776.
29. Klausen M., Heydorn A., Ragas P., Lambertsen L., Aaes-Jorgensen A., Molin S., Tolker-Nielsen T. Biofilm formation by Pseudomonas aeruginosa wild type, flagella and type IV pili mutants. Mol. Microbiol. 2003, 48:1511-1524.
30. Klausen M., Aaes-Jorgensen A., Molin S., Tolker-Nielsen T. Involvement of bacterial migration in the development of complex multicellular structures in Pseudomonas aeruginosa biofilms. Mol. Microbiol. 2003, 50:61-68.
31. Gjermansen M., Ragas P., Sternberg C., Molin S., Tolker-Nielsen T. Characterization of starvation-induced dispersion in Pseudomonas putida biofilms. Environ. Microbiol. 2005, 7:894-906.
32. Allesen-Holm M., Barken K.B., Yang L., Klausen M., Webb J.S., Kjelleberg S., Molin S., Givskov M., Tolker-Nielsen T. A characterization of DNA release in Pseudomonas aeruginosa cultures and biofilms. Mol. Microbiol. 2006, 59:1114-1128.
33. Yang L., Barken K.B., Skindersoe M.E., Christensen A.B., Givskov M., Tolker-Nielsen T. Effects of iron on DNA release and biofilm development by Pseudomonas aeruginosa. Microbiology 2007, 153:1318-1328.
34. Hengge R. Principles of c-di-GMP signalling in bacteria. Nat. Rev. Microbiol. 2009, 7:263-273.
35. Hentzer M., Eberl L., Givskov M. Transcriptome analysis of Pseudomonas aeruginosa biofilm development: anaerobic respiration and iron limitation. Biofilms 2005, 2:37-61.
36. Whiteley M., Bangera M.G., Bumgarner R.E., Parsek M.R., Teitzel G.M., Lory S., Greenberg E.P. Gene expression in Pseudomonas aeruginosa biofilms. Nature 2001, 413:860-864.
37. Schuster M., Lostroh C.P., Ogi T., Greenberg E.P. Identification, timing, and signal specificity of Pseudomonas aeruginosa quorum-controlled genes: a transcriptome analysis. J. Bacteriol. 2003, 185:2066-2079.
38. Wagner V.E., Bushnell D., Passador L., Brooks A.I., Iglewski B.H. Microarray analysis of Pseudomonas aeruginosa quorum-sensing regulons: effects of growth phase and environment. J. Bacteriol. 2003, 185:2080-2095.
39. Kobayashi N., Bauer T.W., Tuohy M.J., Fujishiro T., Procop G.W. Brief ultrasonication improves detection of biofilm-formative bacteria around a metal implant. Clin. Orthop. Relat. Res. 2007, 457:210-213.
40. Domingue G., Ellis B., Dasgupta M., Costerton J.W. Testing antimicrobial susceptibilities of adherent bacteria by a method that incorporates guidelines of the National Committee for Clinical Laboratory Standards. J. Clin. Microbiol. 1994, 32:2564-2568.
41. Moskowitz S.M., Foster J.M., Emerson J., Burns J.L. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J. Clin. Microbiol. 2004, 42:1915-1922.
42. Juhas M., Eberl L., Tummler B. Quorum sensing: the power of cooperation in the world of Pseudomonas. Environ. Microbiol. 2005, 7:459-471.
43. Pesci E.C., Pearson J.P., Seed P.C., Iglewski B.H. Regulation of las and rhl quorum sensing in Pseudomonas aeruginosa. J. Bacteriol. 1997, 179:3127-3132.
44. Dubern J.F., Diggle S.P. Quorum sensing by 2-alkyl-4-quinolones in Pseudomonas aeruginosa and other bacterial species. Mol. Biosyst. 2008, 4:882-888.
45. Latifi A., Foglino M., Tanaka K., Williams P., Lazdunski A. A hierarchical quorum-sensing cascade in Pseudomonas aeruginosa links the transcriptional activators LasR and RhIR (VsmR) to expression of the stationary-phase sigma factor RpoS. Mol. Microbiol. 1996, 21:1137-1146.
46. Pesci E.C., Milbank J.B., Pearson J.P., McKnight S., Kende A.S., Greenberg E.P., Iglewski B.H. Quinolone signaling in the cell-to-cell communication system of Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:11229-11234.
47. Steindler L., Bertani I., De S.L., Schwager S., Eberl L., Venturi V. LasI/R and RhlI/R quorum sensing in a strain of Pseudomonas aeruginosa beneficial to plants. Appl. Environ. Microbiol. 2009, 75:5131-5140.
48. Passador L., Cook J.M., Gambello M.J., Rust L., Iglewski B.H. Expression of Pseudomonas aeruginosa virulence genes requires cell-to- cell communication. Science 1993, 260:1127-1130.
49. Davies D.G., Parsek M.R., Pearson J.P., Iglewski B.H., Costerton J.W., Greenberg E.P. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 1998, 280:295-298.
50. Whitchurch C.B., Tolker-Nielsen T., Ragas P.C., Mattick J.S. Extracellular DNA required for bacterial biofilm formation. Science 2002, 295:1487.
51. Diggle S.P., Winzer K., Chhabra S.R., Worrall K.E., Camara M., Williams P. The Pseudomonas aeruginosa quinolone signal molecule overcomes the cell density-dependency of the quorum sensing hierarchy, regulates rhl-dependent genes at the onset of stationary phase and can be produced in the absence of LasR. Mol. Microbiol. 2003, 50:29-43.
52. Yang L., Nilsson M., Gjermansen M., Givskov M., Tolker-Nielsen T. Pyoverdine and PQS mediated subpopulation interactions involved in Pseudomonas aeruginosa biofilm formation. Mol. Microbiol. 2009, 74:1380-1392.
53. Haussler S., Becker T. The pseudomonas quinolone signal (PQS) balances life and death in Pseudomonas aeruginosa populations. PLoS Pathog. 2008, 4:e1000166.
54. Davey M.E., Caiazza N.C., O'Toole G.A. Rhamnolipid surfactant production affects biofilm architecture in Pseudomonas aeruginosa PAO1. J. Bacteriol. 2003, 185:1027-1036.
55. Boles B.R., Thoendel M., Singh P.K. Rhamnolipids mediate detachment of Pseudomonas aeruginosa from biofilms. Mol. Microbiol. 2005, 57:1210-1223.
56. Pamp S.J., Tolker-Nielsen T. Multiple roles of biosurfactants in structural biofilm development by Pseudomonas aeruginosa. J. Bacteriol. 2007, 189:2531-2539.
57. Alhede M., Bjarnsholt T., Jensen P.O., Phipps R.K., Moser C., Christophersen L., Christensen L.D., van G.M., Parsek M., Hoiby N., Rasmussen T.B., Givskov M. Pseudomonas aeruginosa recognizes and responds aggressively to the presence of polymorphonuclear leukocytes. Microbiology 2009, 155:3500-3508.
58. Winzer K., Falconer C., Garber N.C., Diggle S.P., Camara M., Williams P. The Pseudomonas aeruginosa lectins PA-IL and PA-IIL are controlled by quorum sensing and by RpoS. J. Bacteriol. 2000, 182:6401-6411.
59. Diggle S.P., Winzer K., Lazdunski A., Williams P., Camara M. Advancing the quorum in Pseudomonas aeruginosa: MvaT and the regulation of N-acylhomoserine lactone production and virulence gene expression. J. Bacteriol. 2002, 184:2576-2586.
60. Tielker D., Hacker S., Loris R., Strathmann M., Wingender J., Wilhelm S., Rosenau F., Jaeger K.E. Pseudomonas aeruginosa lectin LecB is located in the outer membrane and is involved in biofilm formation. Microbiology 2005, 151:1313-1323.
61. Diggle S.P., Stacey R.E., Dodd C., Camara M., Williams P., Winzer K. The galactophilic lectin, LecA, contributes to biofilm development in Pseudomonas aeruginosa. Environ. Microbiol. 2006, 8:1095-1104.
62. Vallet I., Olson J.W., Lory S., Lazdunski A., Filloux A. The chaperone/usher pathways of Pseudomonas aeruginosa: identification of fimbrial gene clusters (cup) and their involvement in biofilm formation. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:6911-6916.
63. Banin E., Vasil M.L., Greenberg E.P. Iron and Pseudomonas aeruginosa biofilm formation. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11076-11081.
64. Worlitzsch D., Tarran R., Ulrich M., Schwab U., Cekici A., Meyer K.C., Birrer P., Bellon G., Berger J., Weiss T., Botzenhart K., Yankaskas J.R., Randell S., Boucher R.C., Doring G. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Invest. 2002, 109:317-325.
65. Yoon S.S., Hennigan R.F., Hilliard G.M., Ochsner U.A., Parvatiyar K., Kamani M.C., Allen H.L., DeKievit T.R., Gardner P.R., Schwab U., Rowe J.J., Iglewski B.H., McDermott T.R., Mason R.P., Wozniak D.J., Hancock R.E., Parsek M.R., Noah T.L., Boucher R.C., Hassett D.J. Pseudomonas aeruginosa anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis. Dev. Cell 2002, 3:593-603.
66. Kolpen M., Hansen C.R., Bjarnsholt T., Moser C., Christensen L.D., van G.M., Ciofu O., Mandsberg L., Kharazmi A., Doring G., Givskov M., Hoiby N., Jensen P.O. Polymorphonuclear leucocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis. Thorax 2010, 65:57-62.
67. Lee B., Schjerling C.K., Kirkby N., Hoffmann N., Borup R., Molin S., Hoiby N., Ciofu O. Mucoid Pseudomonas aeruginosa isolates maintain the biofilm formation capacity and the gene expression profiles during the chronic lung infection of CF patients. APMIS 2011, 119:263-274.
68. Dhar N., McKinney J.D. Microbial phenotypic heterogeneity and antibiotic tolerance. Curr. Opin. Microbiol. 2007, 10:30-38.
69. Walters M.C., Roe F., Bugnicourt A., Franklin M.J., Stewart P.S. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob. Agents Chemother. 2003, 47:317-323.
70. Chiang W.C., Nilsson M., Jensen P.O., Hoiby N., Nielsen T.E., Givskov M., Tolker-Nielsen T. Extracellular DNA shields against aminoglycosides in Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 2013, 57:2352-2361.
71. Hentzer M., Teitzel G.M., Balzer G.J., Heydorn A., Molin S., Givskov M., Parsek M.R. Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. J. Bacteriol. 2001, 183:5395-5401.
72. Alipour M., Suntres Z.E., Omri A. Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa. J. Antimicrob. Chemother. 2009, 64:317-325.
73. Werner E., Roe F., Bugnicourt A., Franklin M.J., Heydorn A., Molin S., Pitts B., Stewart P.S. Stratified growth in Pseudomonas aeruginosa biofilms. Appl. Environ. Microbiol. 2004, 70:6188-6196.
74. Pamp S.J., Gjermansen M., Johansen H.K., Tolker-Nielsen T. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol. Microbiol. 2008, 68:223-240.
75. Bjarnsholt T., Jensen P.O., Burmolle M., Hentzer M., Haagensen J.A., Hougen H.P., Calum H., Madsen K.G., Moser C., Molin S., Hoiby N., Givskov M. Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent. Microbiology 2005, 151:373-383.
76. Banin E., Brady K.M., Greenberg E.P. Chelator-induced dispersal and killing of Pseudomonas aeruginosa cells in a biofilm. Appl. Environ. Microbiol. 2006, 72:2064-2069.
77. Haagensen J.A., Klausen M., Ernst R.K., Miller S.I., Folkesson A., Tolker-Nielsen T., Molin S. Differentiation and distribution of colistin- and sodium dodecyl sulfate-tolerant cells in Pseudomonas aeruginosa biofilms. J. Bacteriol. 2007, 189:28-37.
78. Kim J., Pitts B., Stewart P.S., Camper A., Yoon J. Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm. Antimicrob. Agents Chemother. 2008, 52:1446-1453.
79. Herrmann G., Yang L., Wu H., Song Z., Wang H., Hoiby N., Ulrich M., Molin S., Riethmuller J., Doring G. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. J. Infect. Dis. 2010, 202:1585-1592.
80. Chiang W.C., Pamp S.J., Nilsson M., Givskov M., Tolker-Nielsen T. The metabolically active subpopulation in Pseudomonas aeruginosa biofilms survives exposure to membrane-targeting antimicrobials via distinct molecular mechanisms. FEMS Immunol. Med. Microbiol. 2012, 65(2):245-256.
81. Mah T.F., Pitts B., Pellock B., Walker G.C., Stewart P.S., O'Toole G.A. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 2003, 426:306-310.
82. Zhang L., Mah T.F. Involvement of a novel efflux system in biofilm-specific resistance to antibiotics. J. Bacteriol. 2008, 190:4447-4452.
83. Liao J., Sauer K. The MerR-like transcriptional regulator BrlR contributes to Pseudomonas aeruginosa biofilm tolerance. J. Bacteriol. 2012, 194:4823-4836.
84. Liao J., Schurr M.J., Sauer K. The MerR-like regulator BrlR confers biofilm tolerance by activating multidrug efflux pumps in Pseudomonas aeruginosa biofilms. J. Bacteriol. 2013, 195:3352-3363.
85. De Kievit T.R., Parkins M.D., Gillis R.J., Srikumar R., Ceri H., Poole K., Iglewski B.H., Storey D.G. Multidrug efflux pumps: expression patterns and contribution to antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 2001, 45:1761-1770.
86. Gillis R.J., White K.G., Choi K.H., Wagner V.E., Schweizer H.P., Iglewski B.H. Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 2005, 49:3858-3867.
87. Buroni S., Matthijs N., Spadaro F., Van A.H., Scoffone V.C., Pasca M.R., Riccardi G., Coenye T. Differential role of RND efflux pumps in antimicrobial drug resistance of sessile and planktonic Burkholderia cenocepacia cells. Antimicrob. Agents Chemother. 2014, 58(12):7424-7429.
88. Poole K. Efflux pumps as antimicrobial resistance mechanisms. Ann. Med. 2007, 39:162-176.
89. Boles B.R., Singh P.K. Endogenous oxidative stress produces diversity and adaptability in biofilm communities. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:12503-12508.
90. Van Acker A.H., Sass A., Bazzini S., De R.K., Udine C., Messiaen T., Riccardi G., Boon N., Nelis H.J., Mahenthiralingam E., Coenye T. Biofilm-grown Burkholderia cepacia complex cells survive antibiotic treatment by avoiding production of reactive oxygen species. PLoS One 2013, 8:e58943.
91. Kvist M., Hancock V., Klemm P. Inactivation of efflux pumps abolishes bacterial biofilm formation. Appl. Environ. Microbiol. 2008, 74:7376-7382.
92. Hassett D.J., Ma J.F., Elkins J.G., McDermott T.R., Ochsner U.A., West S.E., Huang C.T., Fredericks J., Burnett S., Stewart P.S., McFeters G., Passador L., Iglewski B.H. Quorum sensing in Pseudomonas aeruginosa controls expression of catalase and superoxide dismutase genes and mediates biofilm susceptibility to hydrogen peroxide. Mol. Microbiol. 1999, 34:1082-1093.
93. Shih P.C., Huang C.T. Effects of quorum-sensing deficiency on Pseudomonas aeruginosa biofilm formation and antibiotic resistance. J. Antimicrob. Chemother. 2002, 49:309-314.
94. Brooun A., Liu S., Lewis K. A dose-response study of antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 2000, 44:640-646.
95. De Groote G., Verstraeten V.N., Fauvart M., Kint C.I., Verbeeck A.M., Beullens S., Cornelis P., Michiels J. Novel persistence genes in Pseudomonas aeruginosa identified by high-throughput screening. FEMS Microbiol. Lett. 2009, 297(1):73-79.
96. Lewis K. Persister cells. Annu. Rev. Microbiol. 2010, 64:357-372.
97. Vazquez-Laslop N., Lee H., Neyfakh A.A. Increased persistence in Escherichia coli caused by controlled expression of toxins or other unrelated proteins. J. Bacteriol. 2006, 188:3494-3497.
98. Maisonneuve E., Shakespeare L.J., Jorgensen M.G., Gerdes K. Bacterial persistence by RNA endonucleases. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:13206-13211.
99. Murakami K., Ono T., Viducic D., Kayama S., Mori M., Hirota K., Nemoto K., Miyake Y. Role for rpoS gene of Pseudomonas aeruginosa in antibiotic tolerance. FEMS Microbiol. Lett. 2005, 242:161-167.
100. Viducic D., Ono T., Murakami K., Susilowati H., Kayama S., Hirota K., Miyake Y. Functional analysis of spoT, relA and dksA genes on quinolone tolerance in Pseudomonas aeruginosa under nongrowing condition. Microbiol. Immunol. 2006, 50:349-357.
101. Moker N., Dean C.R., Tao J. Pseudomonas aeruginosa increases formation of multidrug-tolerant persister cells in response to quorum-sensing signaling molecules. J. Bacteriol. 2010, 192:1946-1955.
102. Drenkard E., Ausubel F.M. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002, 416:740-743.
103. Kohanski M.A., Dwyer D.J., Hayete B., Lawrence C.A., Collins J.J. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 2007, 130:797-810.
104. Kohanski M.A., Dwyer D.J., Collins J.J. How antibiotics kill bacteria: from targets to networks. Nat. Rev. Microbiol. 2010, 8:423-435.
105. Van Acker A.H., Van D.P., Coenye T. Molecular mechanisms of antimicrobial tolerance and resistance in bacterial and fungal biofilms. Trends Microbiol. 2014, 22:326-333.
106. Kalghatgi S., Spina C.S., Costello J.C., Liesa M., Morones-Ramirez J.R., Slomovic S., Molina A., Shirihai O.S., Collins J.J. Bactericidal antibiotics induce mitochondrial dysfunction and oxidative damage in Mammalian cells. Sci. Transl. Med. 2013, 5:192ra85.
107. Imlay J.A. Pathways of oxidative damage. Annu. Rev. Microbiol. 2003, 57:395-418.
108. Foti J.J., Devadoss B., Winkler J.A., Collins J.J., Walker G.C. Oxidation of the guanine nucleotide pool underlies cell death by bactericidal antibiotics. Science 2012, 336:315-319.
109. Brochmann R.P., Toft A., Ciofu O., Briales A., Kolpen M., Hempel C., Bjarnsholt T., Hoiby N., Jensen P.O., Jensen P.O. Bactericidal effect of colistin on planktonic Pseudomonas aeruginosa is independent of hydroxyl radical formation. Int. J. Antimicrob. Agents 2014, 43(2):140-147.
110. Jensen P.O., Briales A., Brochmann R.P., Wang H., Kragh K.N., Kolpen M., Hempel C., Bjarnsholt T., Hoiby N., Ciofu O. Formation of hydroxyl radicals contributes to the bactericidal activity of ciprofloxacin against Pseudomonas aeruginosa biofilms. Pathog. Dis. 2014, 70:440-443.
111. Albesa I., Becerra M.C., Battan P.C., Paez P.L. Oxidative stress involved in the antibacterial action of different antibiotics. Biochem. Biophys. Res. Commun. 2004, 317:605-609.
112. Battan P.C., Barnes A.I., Albesa I. Resistance to oxidative stress caused by ceftazidime and piperacillin in a biofilm of Pseudomonas. Luminescence 2004, 19:265-270.
113. Stewart P.S., Franklin M.J. Physiological heterogeneity in biofilms. Nat. Rev. Microbiol. 2008, 6:199-210.
114. Morones-Ramirez J.R., Winkler J.A., Spina C.S., Collins J.J. Silver enhances antibiotic activity against gram-negative bacteria. Sci. Transl. Med. 2013, 5:190ra81.
115. Keren I., Wu Y., Inocencio J., Mulcahy L.R., Lewis K. Killing by bactericidal antibiotics does not depend on reactive oxygen species. Science 2013, 339:1213-1216.
116. Liu Y., Imlay J.A. Cell death from antibiotics without the involvement of reactive oxygen species. Science 2013, 339:1210-1213.
117. Dwyer D.J., Belenky P.A., Yang J.H., MacDonald I.C., Martell J.D., Takahashi N., Chan C.T., Lobritz M.A., Braff D., Schwarz E.G., Ye J.D., Pati M., Vercruysse M., Ralifo P.S., Allison K.R., Khalil A.S., Ting A.Y., Walker G.C., Collins J.J. Antibiotics induce redox-related physiological alterations as part of their lethality. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:E2100-E2109.
118. Driffield K., Miller K., Bostock J.M., O'Neill A.J., Chopra I. Increased mutability of Pseudomonas aeruginosa in biofilms. J. Antimicrob. Chemother. 2008, 61:1053-1056.
119. Conibear T.C., Collins S.L., Webb J.S. Role of mutation in Pseudomonas aeruginosa biofilm development. PLoS One 2009, 4:e6289.
120. Mai-Prochnow A., Lucas-Elio P., Egan S., Thomas T., Webb J.S., Sanchez-Amat A., Kjelleberg S. Hydrogen peroxide linked to lysine oxidase activity facilitates biofilm differentiation and dispersal in several gram-negative bacteria. J. Bacteriol. 2008, 190:5493-5501.
121. Barraud N., Hassett D.J., Hwang S.H., Rice S.A., Kjelleberg S., Webb J.S. Involvement of nitric oxide in biofilm dispersal of Pseudomonas aeruginosa. J. Bacteriol. 2006, 188:7344-7353.
122. Park S., You X., Imlay J.A. Substantial DNA damage from submicromolar intracellular hydrogen peroxide detected in Hpx- mutants of Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9317-9322.
123. Ciofu O., Riis B., Pressler T., Poulsen H.E., Hoiby N. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob. Agents Chemother. 2005, 49:2276-2282.
124. Ciofu O., Giwercman B., Pedersen S.S., Hoiby N. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center. APMIS 1994, 102:674-680.
125. Ciofu O. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response. APMIS Suppl. 2003, 1-47.
126. Jalal S., Ciofu O., Hoiby N., Gotoh N., Wretlind B. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob. Agents Chemother. 2000, 44:710-712.
127. Islam S., Oh H., Jalal S., Karpati F., Ciofu O., Hoiby N., Wretlind B. Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Clin. Microbiol. Infect. 2009, 15:60-66.
128. Mulet X., Macia M.D., Mena A., Juan C., Perez J.L., Oliver A. Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. Antimicrob. Agents Chemother. 2009, 53:1552-1560.
129. Poole K. Bacterial multidrug efflux pumps serve other functions. Microbe 2008, 3:179-185.
130. Mandsberg L.F., Ciofu O., Kirkby N., Christiansen L.E., Poulsen H.E., Hoiby N. Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. Antimicrob. Agents Chemother. 2009, 53:2483-2491.
131. Johansen H.K., Moskowitz S.M., Ciofu O., Pressler T., Hoiby N. Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J. Cyst. Fibros. 2008, 7:391-397.
132. Marvig R.L., Sondergaard M.S., Damkiaer S., Hoiby N., Johansen H.K., Molin S., Jelsbak L. Mutations in 23S rRNA confer resistance against azithromycin in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2012, 56:4519-4521.
133. Bjarnsholt T., Ciofu O., Molin S., Givskov M., Hoiby N. Applying insights from biofilm biology to drug development - can a new approach be developed?. Nat. Rev. Drug Discov. 2013, 12:791-808.
134. Jensen P.O., Bjarnsholt T., Phipps R., Rasmussen T.B., Calum H., Christoffersen L., Moser C., Williams P., Pressler T., Givskov M., Hoiby N. Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by Pseudomonas aeruginosa. Microbiology 2007, 153:1329-1338.
135. van G.M., Christensen L.D., Alhede M., Phipps R., Jensen P.O., Christophersen L., Pamp S.J., Moser C., Mikkelsen P.J., Koh A.Y., Tolker-Nielsen T., Pier G.B., Hoiby N., Givskov M., Bjarnsholt T. Inactivation of the rhlA gene in Pseudomonas aeruginosa prevents rhamnolipid production, disabling the protection against polymorphonuclear leukocytes. APMIS 2009, 117:537-546.
136. Givskov M., de Nys R., Manefield M., Gram L., Maximilien R., Eberl L., Molin S., Steinberg P.D., Kjelleberg S. Eukaryotic interference with homoserine lactone-mediated prokaryotic signalling. J. Bacteriol. 1996, 178:6618-6622.
137. de Nys R., Wright A.D., Konig G.M., Sticher O. New halogenated furanones from the marine alga Delisea pulchra (cf. fimbriata). Tetrahedron 1993, 49:11213-11220.
138. Hentzer M., Riedel K., Rasmussen T.B., Heydorn A., Andersen J.B., Parsek M.R., Rice S.A., Eberl L., Molin S., Hoiby N., Kjelleberg S., Givskov M. Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated furanone compound. Microbiology 2002, 148:87-102.
139. Hentzer M., Wu H., Andersen J.B., Riedel K., Rasmussen T.B., Bagge N., Kumar N., Schembri M.A., Song Z., Kristoffersen P., Manefield M., Costerton J.W., Molin S., Eberl L., Steinberg P., Kjelleberg S., Hoiby N., Givskov M. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. Embo J. 2003, 22:3803-3815.
140. Rasch M., Buch C., Austin B., Slierendrecht W.J., Ekmann K.S., Larsen J.L., Johansen C., Riedel K., Eberl L., Givskov M., Gram L. An inhibitor of bacterial quorum sensing reduces mortalities caused by Vibriosis in rainbow trout (Oncorhynchus mykiss, Walbaum). Syst. Appl. Microbiol. 2004, 27:350-359.
141. Wu H., Song Z., Hentzer M., Andersen J.B., Molin S., Givskov M., Hoiby N. Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice. J. Antimicrob. Chemother. 2004, 53:1054-1061.
142. Christensen L.D., Moser C., Jensen P.O., Rasmussen T.B., Christophersen L., Kjelleberg S., Kumar N., Hoiby N., Givskov M., Bjarnsholt T. Impact of Pseudomonas aeruginosa quorum sensing on biofilm persistence in an in vivo intraperitoneal foreign-body infection model. Microbiology 2007, 153:2312-2320.
143. Christensen L.D., van G.M., Jakobsen T.H., Alhede M., Hougen H.P., Hoiby N., Bjarnsholt T., Givskov M. Synergistic antibacterial efficacy of early combination treatment with tobramycin and quorum-sensing inhibitors against Pseudomonas aeruginosa in an intraperitoneal foreign-body infection mouse model. J. Antimicrob. Chemother. 2012, 67:1198-1206.
144. Brackman G., Cos P., Maes L., Nelis H.J., Coenye T. Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo. Antimicrob. Agents Chemother. 2011, 55:2655-2661.
145. Kim C., Kim J., Park H.Y., Park H.J., Lee J.H., Kim C.K., Yoon J. Furanone derivatives as quorum-sensing antagonists of Pseudomonas aeruginosa. Appl. Microbiol. Biotechnol. 2008, 80:37-47.
146. Olsen J.A., Severinsen R., Rasmussen T.B., Hentzer M., Givskov M., Nielsen J. Synthesis of new 3- and 4-substituted analogues of acyl homoserine lactone quorum sensing autoinducers. Bioorg. Med. Chem. Lett. 2002, 12:325-328.
147. Persson T., Hansen T.H., Rasmussen T.B., Skinderso M.E., Givskov M., Nielsen J. Rational design and synthesis of new quorum-sensing inhibitors derived from acylated homoserine lactones and natural products from garlic. Org. Biomol. Chem. 2005, 3:253-262.
148. Muh U., Schuster M., Heim R., Singh A., Olson E.R., Greenberg E.P. Novel Pseudomonas aeruginosa quorum-sensing inhibitors identified in an ultra-high-throughput screen. Antimicrob. Agents Chemother. 2006, 50:3674-3679.
149. Geske G.D., O'Neill J.C., Miller D.M., Mattmann M.E., Blackwell H.E. Modulation of bacterial quorum sensing with synthetic ligands: systematic evaluation of N-acylated homoserine lactones in multiple species and new insights into their mechanisms of action. J. Am. Chem. Soc. 2007, 129:13613-13625.
150. Geske G.D., O'Neill J.C., Blackwell H.E. Expanding dialogues: from natural autoinducers to non-natural analogues that modulate quorum sensing in Gram-negative bacteria. Chem. Soc. Rev. 2008, 37:1432-1447.
151. Mattmann M.E., Geske G.D., Worzalla G.A., Chandler J.R., Sappington K.J., Greenberg E.P., Blackwell H.E. Synthetic ligands that activate and inhibit a quorum-sensing regulator in Pseudomonas aeruginosa. Bioorg. Med. Chem. Lett. 2008, 18:3072-3075.
152. Stacy D.M., Le Quement S.T., Hansen C.L., Clausen J.W., Tolker-Nielsen T., Brummond J.W., Givskov M., Nielsen T.E., Blackwell H.E. Synthesis and biological evaluation of triazole-containing N-acyl homoserine lactones as quorum sensing modulators. Org. Biomol. Chem. 2013, 11:938-954.
153. Skindersoe M.E., Ettinger-Epstein P., Rasmussen T.B., Bjarnsholt T., de N.R., Givskov M. Quorum sensing antagonism from marine organisms. Mar. Biotechnol. (NY) 2008, 10:56-63.
154. Jakobsen T.H., van G.M., Phipps R.K., Shanmugham M.S., Christensen L.D., Alhede M., Skindersoe M.E., Rasmussen T.B., Friedrich K., Uthe F., Jensen P.O., Moser C., Nielsen K.F., Eberl L., Larsen T.O., Tanner D., Hoiby N., Bjarnsholt T., Givskov M. Ajoene, a sulfur-rich molecule from garlic, inhibits genes controlled by quorum sensing. Antimicrob. Agents Chemother. 2012, 56:2314-2325.
155. Jakobsen T.H., Bragason S.K., Phipps R.K., Christensen L.D., van G.M., Alhede M., Skindersoe M., Larsen T.O., Hoiby N., Bjarnsholt T., Givskov M. Food as a source for quorum sensing inhibitors: iberin from horseradish revealed as a quorum sensing inhibitor of Pseudomonas aeruginosa. Appl. Environ. Microbiol. 2012, 78:2410-2421.
156. Rasmussen T.B., Skindersoe M.E., Bjarnsholt T., Phipps R.K., Christensen K.B., Jensen P.O., Andersen J.B., Koch B., Larsen T.O., Hentzer M., Eberl L., Hoiby N., Givskov M. Identity and effects of quorum-sensing inhibitors produced by Penicillium species. Microbiology 2005, 151:1325-1340.
157. Tateda K., Comte R., Pechere J.C., Kohler T., Yamaguchi K., van Delden C. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2001, 45:1930-1933.
158. Skindersoe M.E., Alhede M., Phipps R., Yang L., Jensen P.O., Rasmussen T.B., Bjarnsholt T., Tolker-Nielsen T., Hoiby N., Givskov M. Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2008, 52:3648-3663.
159. Hoffmann N., Lee B., Hentzer M., Rasmussen T.B., Song Z., Johansen H.K., Givskov M., Hoiby N. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. Antimicrob. Agents Chemother. 2007, 51:3677-3687.
160. Hansen C.R., Pressler T., Koch C., Hoiby N. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J. Cyst. Fibros. 2005, 4:35-40.
161. Bottomley M.J., Muraglia E., Bazzo R., Carfi A. Molecular insights into quorum sensing in the human pathogen Pseudomonas aeruginosa from the structure of the virulence regulator LasR bound to its autoinducer. J. Biol. Chem. 2007, 282:13592-13600.
162. Yang L., Rybtke M.T., Jakobsen T.H., Hentzer M., Bjarnsholt T., Givskov M., Tolker-Nielsen T. Computer-aided identification of recognized drugs as Pseudomonas aeruginosa quorum-sensing inhibitors. Antimicrob. Agents Chemother. 2009, 53:2432-2443.
163. Amara N., Mashiach R., Amar D., Krief P., Spieser S.A., Bottomley M.J., Aharoni A., Meijler M.M. Covalent inhibition of bacterial quorum sensing. J. Am. Chem. Soc. 2009, 131:10610-10619.
164. Smyth A.R., Cifelli P.M., Ortori C.A., Righetti K., Lewis S., Erskine P., Holland E.D., Givskov M., Williams P., Camara M., Barrett D.A., Knox A. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis-a pilot randomized controlled trial. Pediatr. Pulmonol. 2010, 45:356-362.
165. van D.C., Kohler T., Brunner-Ferber F., Francois B., Carlet J., Pechere J.C. Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial. Intensive Care Med. 2012, 38:1118-1125.
166. Ciofu O., Mandsberg L.F., Bjarnsholt T., Wassermann T., Hoiby N. Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants. Microbiology 2010, 156:1108-1119.
167. Fleet J.E., Guha K., Piper S., Banya W., Bilton D., Hodson M.E. A retrospective analysis of the impact of azithromycin maintenance therapy on adults attending a UK cystic fibrosis clinic. J. Cyst. Fibros. 2013, 12:49-53.
168. Mueller M., de la Pena A., Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob. Agents Chemother. 2004, 48:369-377.
169. Hengzhuang W., Ciofu O., Yang L., Wu H., Song Z., Oliver A., Hoiby N. High beta-lactamase levels change the pharmacodynamics of beta-lactam antibiotics in pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 2013, 57:196-204.
170. Hengzhuang W., Wu H., Ciofu O., Song Z., Hoiby N. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob. Agents Chemother. 2012, 56:2683-2690.
171. Hengzhuang W., Wu H., Ciofu O., Song Z., Hoiby N. Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 2011, 55:4469-4474.
172. Döring G., Conway S.P., Heijerman H.G., Hodson M.E., Høiby N., myth A., ouw D.J. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur. Respir. J. 2000, 16:749-767.
173. Pedersen S.S., Jensen T., Osterhammel D., Osterhammel P. Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis. Antimicrob. Agents Chemother. 1987, 31:594-599.
174. Yeaman M.R., Yount N.Y. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 2003, 55:27-55.
175. Yount N.Y., Yeaman M.R. Immunocontinuum: perspectives in antimicrobial peptide mechanisms of action and resistance. Protein Pept. Lett. 2005, 12:49-67.
176. Drusano G.L. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat. Rev. Microbiol. 2004, 2:289-300.
177. Gumbo T., Louie A., Deziel M.R., Parsons L.M., Salfinger M., Drusano G.L. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis. 2004, 190:1642-1651.
178. Lodise T.P., Lomaestro B., Drusano G.L. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin. Infect. Dis. 2007, 44:357-363.
179. Li J., Nation R.L., Turnidge J.D., Milne R.W., Coulthard K., Rayner C.R., Paterson D.L. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis. 2006, 6:589-601.
180. Giwercman B., Jensen E.T., Hoiby N., Kharazmi A., Costerton J.W. Induction of beta-lactamase production in Pseudomonas aeruginosa biofilm. Antimicrob. Agents Chemother. 1991, 35:1008-1010.
181. Ciofu O., Tolker-Nielsen T. Antibiotic tolerance and resistance in biofilms. Biofilm Infections 2011, 215-229. Springer. T. Bjarnsholt, C. Moser, P.O. Jensen, N. Høiby (Eds.).
182. Bagge N., Hentzer M., Andersen J.B., Ciofu O., Givskov M., Hoiby N. Dynamics and spatial distribution of beta-lactamase expression in Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 2004, 48:1168-1174.
183. Bagge N., Schuster M., Hentzer M., Ciofu O., Givskov M., Greenberg E.P., Hoiby N. Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and beta-lactamase and alginate production. Antimicrob. Agents Chemother. 2004, 48:1175-1187.
184. Ciofu O., Beveridge T.J., Kadurugamuwa J., Walther-Rasmussen J., Hoiby N. Chromosomal beta-lactamase is packaged into membrane vesicles and secreted from Pseudomonas aeruginosa. J. Antimicrob. Chemother. 2000, 45:9-13.
185. Ciofu O., Jensen T., Pressler T., Johansen H.K., Koch C., Hoiby N. Meropenem in cystic fibrosis patients infected with resistant Pseudomonas aeruginosa or Burkholderia cepacia and with hypersensitivity to beta-lactam antibiotics. Clin. Microbiol. Infect. 1996, 2:91-98.
186. Jaccard C., Troillet N., Harbarth S., Zanetti G., Aymon D., Schneider R., Chiolero R., Ricou B., Romand J., Huber O., Ambrosetti P., Praz G., Lew D., Bille J., Glauser M.P., Cometta A. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob. Agents Chemother. 1998, 42:2966-2972.
187. Alkawash M.A., Soothill J.S., Schiller N.L. Alginate lyase enhances antibiotic killing of mucoid Pseudomonas aeruginosa in biofilms. APMIS 2006, 114:131-138.
188. Kolodkin-Gal I., Romero D., Cao S., Clardy J., Kolter R., Losick R. D-amino acids trigger biofilm disassembly. Science 2010, 328:627-629.
189. Liu Y., Yang L., Molin S. Synergistic activities of an efflux pump inhibitor and iron chelators against Pseudomonas aeruginosa growth and biofilm formation. Antimicrob. Agents Chemother. 2010, 54:3960-3963.
190. Döring G., Flume P., Heijerman H., Elborn J.S. Treatment of lung infection in patients with cystic fibrosis: Current and future strategies. J. Cyst. Fibros. 2012, 11:461-479.
191. Flume P.A., O'Sullivan B.P., Robinson K.A., Goss C.H., Mogayzel P.J., Willey-Courand D.B., Bujan J., Finder J., Lester M., Quittell L., Rosenblatt R., Vender R.L., Hazle L., Sabadosa K., Marshall B. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am. J. Respir. Crit. Care Med. 2007, 176:957-969.
192. Høiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med. 2011, 9:32.
193. Wolter J., Seeney S., Bell S., Bowler S., Masel P., McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002, 57:212-216.
194. Saiman L., Marshall B.C., Mayer-Hamblett N., Burns J.L., Quittner A.L., Cibene D.A., Coquillette S., Fieberg A.Y., Accurso F.J., Campbell P.W. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003, 290:1749-1756.
195. Saiman L., Mayer-Hamblett N., Anstead M., Lands L.C., Kloster M., Goss C.H., Rose L.M., Burns J.L., Marshall B.C., Ratjen F. Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatr. Pulmonol. 2012, 47:641-648.
196. Aanaes K., Eickhardt S., Johansen H.K., von Buchwald C., Skov M., Høiby N., Bjarnsholt T. Azithromycin in cystic fibrosis. Pharmacokinetic and therapeutic aspects of maintenance therapy 2012.
197. Aanaes K., Eickhardt S., Johansen H.K., von B.C., Skov M., Hoiby N., Bjarnsholt T. Sinus biofilms in patients with cystic fibrosis: is adjusted eradication therapy needed?. Eur. Arch. Otorhinolaryngol. 2014, (Epub ahead of print).
198. Johansen H.K., Hoiby N. Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax 1992, 47:109-111.
199. de Vrankrijker A.M., Wolfs T.F., Ciofu O., Hoiby N., van der Ent C.K., Poulsen S.S., Johansen H.K. Respiratory syncytial virus infection facilitates acute colonization of Pseudomonas aeruginosa in mice. J. Med. Virol. 2009, 81:2096-2103.
200. Hansen S.K., Rau M.H., Johansen H.K., Ciofu O., Jelsbak L., Yang L., Folkesson A., Jarmer H.O., Aanaes K., von B.C., Hoiby N., Molin S. Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection. ISME J. 2012, 6:31-45.
201. Johansen H.K., Aanaes K., Pressler T., Nielsen K.G., Fisker J., Skov M., Hoiby N., von B.C. Colonisation and infection of the paranasal sinuses in cystic fibrosis patients is accompanied by a reduced PMN response. J. Cyst. Fibros. 2012, 11:525-531.
202. Fothergill J.L., Neill D.R., Loman N., Winstanley C., Kadioglu A. Pseudomonas aeruginosa adaptation in the nasopharyngeal reservoir leads to migration and persistence in the lungs. Nat. Commun. 2014, 5:4780.
203. Douglas T.A., Brennan S., Gard S., Berry L., Gangell C., Stick S.M., Clements B.S., Sly P.D. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur. Respir. J. 2009, 33:305-311.
204. Stick S.M., Brennan S., Murray C., Douglas T., von Ungern-Sternberg B.S., Garratt L.W., Gangell C.L., De K.N., Linnane B., Ranganathan S., Robinson P., Robertson C., Sly P.D. Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. J. Pediatr. 2009, 155:623-628.
205. Sly P.D., Brennan S., Gangell C., De K.N., Murray C., Mott L., Stick S.M., Robinson P.J., Robertson C.F., Ranganathan S.C. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am. J. Respir. Crit. Care Med. 2009, 180:146-152.
206. de Jong P.A., Nakano Y., Lequin M.H., Mayo J.R., Woods R., Pare P.D., Tiddens H.A. Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis. Eur. Respir. J. 2004, 23:93-97.
207. Ulrich M., Worlitzsch D., Viglio S., Siegmann N., Iadarola P., Shute J.K., Geiser M., Pier G.B., Friedel G., Barr M.L., Schuster A., Meyer K.C., Ratjen F., Bjarnsholt T., Gulbins E., Doring G. Alveolar inflammation in cystic fibrosis. J. Cyst. Fibros. 2010, 9:217-227.
208. Hassett D.J., Korfhagen T.R., Irvin R.T., Schurr M.J., Sauer K., Lau G.W., Sutton M.D., Yu H., Hoiby N. Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies. Expert Opin. Ther. Targets 2010, 14:117-130.
209. Kolpen M., Bjarnsholt T., Moser C., Hansen C.R., Rickelt L.F., Kuhl M., Hempel C., Pressler T., Hoiby N., Jensen P.O. Nitric Oxide Production by Polymorphonuclear Leukocytes in Infected Cystic Fibrosis Sputum Consumes Oxygen. Clin. Exp. Immunol. 2014, 177(1):310-319.
210. Kolpen M., Kuhl M., Bjarnsholt T., Moser C., Hansen C.R., Liengaard L., Kharazmi A., Pressler T., Hoiby N., Jensen P.O. Nitrous oxide production in sputum from cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. PLoS One 2014, 9:e84353.
211. Aanaes K., Rickelt L.F., Johansen H.K., von B.C., Pressler T., Hoiby N., Jensen P.O. Decreased mucosal oxygen tension in the maxillary sinuses in patients with cystic fibrosis. J. Cyst. Fibros. 2011, 10:114-120.
212. Behrends V., Ryall B., Zlosnik J.E., Speert D.P., Bundy J.G., Williams H.D. Metabolic adaptations of Pseudomonas aeruginosa during cystic fibrosis chronic lung infections. Environ. Microbiol. 2013, 15:398-408.
213. Rau M.H., Hansen S.K., Johansen H.K., Thomsen L.E., Workman C.T., Nielsen K.F., Jelsbak L., Hoiby N., Yang L., Molin S. Early adaptive developments of Pseudomonas aeruginosa after the transition from life in the environment to persistent colonization in the airways of human cystic fibrosis hosts. Environ. Microbiol. 2010, 12:1643-1658.
214. Pedersen S.S., Kharazmi A., Espersen F., Hoiby N. Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response. Infect. Immun. 1990, 58:3363-3368.
215. Høiby N. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. A survey. Acta Pathol. Microbiol. Scand. Suppl. 1977, 262:1-96.
216. Pedersen S.S., Hoiby N., Espersen F., Koch C. Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax 1992, 47:6-13.
217. Govan J.R., Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol. Rev. 1996, 60:539-574.
218. Ciofu O., Fussing V., Bagge N., Koch C., Hoiby N. Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting. J. Antimicrob. Chemother. 2001, 48:391-396.
219. Oliver A., Canton R., Campo P., Baquero F., Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000, 288:1251-1254.
220. Workentine M.L., Sibley C.D., Glezerson B., Purighalla S., Norgaard-Gron J.C., Parkins M.D., Rabin H.R., Surette M.G. Phenotypic heterogeneity of Pseudomonas aeruginosa populations in a cystic fibrosis patient. PLoS One 2013, 8:e60225.
221. Mowat E., Paterson S., Fothergill J.L., Wright E.A., Ledson M.J., Walshaw M.J., Brockhurst M.A., Winstanley C. Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections. Am. J. Respir. Crit. Care Med. 2011, 183(12):1674-1679.
222. Fothergill J.L., Mowat E., Walshaw M.J., Ledson M.J., James C.E., Winstanley C. Effect of antibiotic treatment on bacteriophage production by a cystic fibrosis epidemic strain of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2011, 55:426-428.
223. Cirz R.T., Romesberg F.E. Controlling mutation: intervening in evolution as a therapeutic strategy. Crit. Rev. Biochem. Mol. Biol. 2007, 42:341-354.
224. Poole K. Bacterial stress responses as determinants of antimicrobial resistance. J. Antimicrob. Chemother. 2012, 67:2069-2089.
225. Cirz R.T., O'Neill B.M., Hammond J.A., Head S.R., Romesberg F.E. Defining the Pseudomonas aeruginosa SOS response and its role in the global response to the antibiotic ciprofloxacin. J. Bacteriol. 2006, 188:7101-7110.
226. Miller C., Thomsen L.E., Gaggero C., Mosseri R., Ingmer H., Cohen S.N. SOS response induction by beta-lactams and bacterial defense against antibiotic lethality. Science 2004, 305:1629-1631.
227. Blazquez J., Gomez-Gomez J.M., Oliver A., Juan C., Kapur V., Martin S. PBP3 inhibition elicits adaptive responses in Pseudomonas aeruginosa. Mol. Microbiol. 2006, 62:84-99.
228. Dwyer D.J., Kohanski M.A., Collins J.J. Role of reactive oxygen species in antibiotic action and resistance. Curr. Opin. Microbiol. 2009, 12:482-489.
229. Baquero F., Coque T.M., de la Cruz F. Ecology and evolution as targets: the need for novel eco-evo drugs and strategies to fight antibiotic resistance. Antimicrob. Agents Chemother. 2011, 55:3649-3660.
230. Kohanski M.A., DePristo M.A., Collins J.J. Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. Mol. Cell 2010, 37:311-320.
231. Jorgensen K.M., Wassermann T., Jensen P.O., Hengzuang W., Molin S., Hoiby N., Ciofu O. Sublethal ciprofloxacin treatment leads to rapid development of high-level ciprofloxacin resistance during long-term experimental evolution of pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2013, 57:4215-4221.
232. Nair C.G., Chao C., Ryall B., Williams H.D. Sub-lethal concentrations of antibiotics increase mutation frequency in the cystic fibrosis pathogen Pseudomonas aeruginosa. Lett. Appl. Microbiol. 2013, 56:149-154.
233. Wright E.A., Fothergill J.L., Paterson S., Brockhurst M.A., Winstanley C. Sub-inhibitory concentrations of some antibiotics can drive diversification of Pseudomonas aeruginosa populations in artificial sputum medium. BMC Microbiol. 2013, 13:170.
234. Mainz J.G., Michl R., Pfister W., Beck J.F. Cystic fibrosis upper airways primary colonization with Pseudomonas aeruginosa: eradicated by sinonasal antibiotic inhalation. Am. J. Respir. Crit. Care Med. 2011, 184:1089-1090.
235. Aanaes K. Bacterial sinusitis can be a focus for initial lung colonisation and chronic lung infection in patients with cystic fibrosis. J. Cyst. Fibros. 2013, 12(Suppl. 2):S1-S20.
236. Macdonald K.I., Gipsman A., Magit A., Fandino M., Massoud E., Witterick I.J., Hong P. Endoscopic sinus surgery in patients with cystic fibrosis: A systematic review and meta-analysis of pulmonary function. Rhinology 2012, 50:360-369.
237. Vital D., Hofer M., Benden C., Holzmann D., Boehler A. Impact of sinus surgery on pseudomonal airway colonization, bronchiolitis obliterans syndrome and survival in cystic fibrosis lung transplant recipients. Respiration 2013, 86(1):25-31.
238. Mainz J.G., Hentschel J., Schien C., Cramer N., Pfister W., Beck J.F., Tummler B. Sinonasal persistence of Pseudomonas aeruginosa after lung transplantation. J. Cyst. Fibros. 2012, 11:158-161.
239. Moriarty T.F., McElnay J.C., Elborn J.S., Tunney M.M. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection. Pediatr. Pulmonol. 2007, 42:1008-1017.
240. Hoffman L.R., D'Argenio D.A., MacCoss M.J., Zhang Z., Jones R.A., Miller S.I. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 2005, 436:1171-1175.
241. Takahashi A., Yomoda S., Ushijima Y., Kobayashi I., Inoue M. Ofloxacin, norfloxacin and ceftazidime increase the production of alginate and promote the formation of biofilm of Pseudomonas aeruginosa in vitro. J. Antimicrob. Chemother. 1995, 36:743-745.
242. Waters V., Ratjen F. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Cochrane Database Syst. Rev. 2012, 11:CD009528.
243. Dwyer D.J., Collins J.J., Walker G.C. Unraveling the physiological complexities of antibiotic lethality. Annu. Rev. Pharmacol. Toxicol. 2015, 55:9.1-9.20. (Epub ahead of print).
244. MacLeod D.L., Barker L.M., Sutherland J.L., Moss S.C., Gurgel J.L., Kenney T.F., Burns J.L., Baker W.R. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J. Antimicrob. Chemother. 2009, 64:829-836.
245. McCaughey G., Gilpin D.F., Schneiders T., Hoffman L.R., McKevitt M., Elborn J.S., Tunney M.M. Fosfomycin and tobramycin in combination downregulate nitrate reductase genes narG and narH, resulting in increased activity against Pseudomonas aeruginosa under anaerobic conditions. Antimicrob. Agents Chemother. 2013, 57:5406-5414.
246. Macia M.D., Borrell N., Segura M., Gomez C., Perez J.L., Oliver A. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2006, 50:975-983.
247. Oliver A., Levin B.R., Juan C., Baquero F., Blazquez J. Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections. Antimicrob. Agents Chemother. 2004, 48:4226-4233.
248. Ren C.L., Konstan M.W., Yegin A., Rasouliyan L., Trzaskoma B., Morgan W.J., Regelmann W. Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis. J. Cyst. Fibros. 2012, 11:293-299.
249. Döring G., Høiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J. Cyst. Fibros. 2004, 3:67-91.